Myeloid cells as therapeutic targets in neuroinflammation after stroke: Specific roles of neutrophils and neutrophil

Abstract

Ischemic brain injury causes a local inflammatory response, involving the activation of resident brain cells such as microglia and the recruitment of infiltrating immune cells. Increasing evidence supports that plasticity of the myeloid cell lineage is determinant for the specific role of these cells on stroke outcome, from initiation and maintenance to resolution of post-ischemic inflammation. The aim of this review is to summarize some of the key characteristics of these cells and the mechanisms for their recruitment into the injured brain through interactions with platelets, endothelial cells and other leukocytes. Also, we discuss the existence of different leukocyte subsets in the ischemic tissue and, specifically, the impact of different myeloid phenotypes on stroke outcome, with special emphasis on neutrophils and their interplay with platelets. Knowledge of these cellular phenotypes and interactions may pave the way to new therapies able to promote protective immune responses and tissue repair after cerebral ischemia.

Keywords

Neuroinflammation cerebral ischemia leukocyte microglia neuroimmune phenotypes

Introduction

Inflammation is recognized as an important contributor to the pathophysiology of stroke. The inflammatory response induces the release of reactive oxygen species (ROS) and promotes immune-derived mechanisms associated with cytotoxicity and brain damage.^1,2 In particular, the innate immune system plays a pivotal role in the evolution of ischemic cerebral injury, as soluble mediators (i.e. cytokines and chemokines) and specialized cells, activated in the brain or recruited from the periphery, actively participate in the detrimental processes implicated in tissue damage.^3,4 In this context, a vast number of experimental studies have explored the beneficial role of anti-inflammatory approaches to block/antagonize key pro-inflammatory pathways driven by cerebral ischemia.² However, the dualistic role exerted by several mediators of the immune reaction may explain why most anti-inflammatory approaches, conceived disregarding the potential beneficial function of the target, have failed to reach the clinical setting.⁵ In addition, the fact that ischemic cerebral injury involves several mechanisms may explain why “single-target” therapies have resulted insufficient, a reason for which it has been proposed that therapeutic approaches should target multiple cell types to promote protection and recovery.⁶ An important factor to consider is that a part of the inflammatory response is its resolution, an active process that involves the participation of myeloid cells with distinct phenotypes, which could reflect either the local conversion of cells from a pro-inflammatory to an anti-inflammatory phenotype or the recruitment of cells with different phenotypes and functions. In this context, whereas polarization of microglia/macrophages has been extensively investigated,⁷ the roles of neutrophils are understudied. Increasing evidence shows the ability of neutrophils to switch towards a variety of phenotypes dependent on specific microenvironmental signals which are related to the spatio-temporal progression of ischemic brain damage.^8–10 Another crucial issue which remains quite unknown is the important impact of the interaction of neutrophils with platelets in the onset of inflammation. Platelets are growingly considered a major actor of the immune response. Their binding to myeloid cells has been shown to enhance their function as well as recruitment to extravascular areas (rev. in Gomez-Moreno et al.¹¹).

The aim of this review is to summarize the roles that have been identified so far for hematopoietic stem cell (HSC)-derived myeloid cell subsets (neutrophils, monocytes and platelets) and resident microglial cells, with a special emphasis on neutrophils and their interaction with platelets in the stroke setting. We focus on the mechanisms that regulate their activation and recruitment to inflamed tissues and on how they contribute to stroke pathogenesis. Also, we highlight the important role of immune cells after stroke and the therapeutic relevance of their polarization as a potential novel target in stroke neuroinflammation. We also propose that potential cell-based treatments using the pleiotropic mechanisms conferred by their polarization towards non-inflammatory phenotypes may be an effective therapeutic strategy to the acute, subacute and chronic phases of this pathology.

Monocytes/macrophages

Monocytes are a population of mononuclear leukocytes that originate in the bone marrow from HSCs and then are released into the circulation as non-dividing cells.¹² These cells represent approximately 4 or 10% of total leukocytes in mice or human peripheral blood, respectively, with a considerable pool located in spleen and lungs, apart from their homing into inflammatory sites in response to specific chemokines.¹³ Monocytes are immune effector cells, equipped with chemokine and pathogen recognition receptors (PRRs) that mediate migration from blood to tissues during infection. Their functions include the killing of pathogens via phagocytosis, the expression of inflammatory cytokines and enzymes and the subsequent production of ROS and reactive nitrogen species (RNS).¹⁴ Under specific conditions, monocytes can stimulate or inhibit T-cell responses during cancer as well as infectious and autoimmune diseases. They are also involved in tissue repair and neovascularization.¹⁵ They can also differentiate into inflammatory dendritic cells (DC) or macrophages during inflammation and constitute the resident pool of macrophages in the lamina propria of the intestine and skin^16,17 in steady state. Monocyte migration to tissues and differentiation to inflammatory DC and macrophages is likely determined by the inflammatory milieu and the activation of pathogen-associated PRRs.¹⁸

Two predominant subsets of circulating monocytes, “inflammatory” and “patrolling” monocytes, are found in the blood of rodents. Short-lived inflammatory monocytes are characterized by the expression of high levels of lymphocyte antigen 6 complex locus C1 (Ly6C), low to intermediate levels of CX(3)-C motif chemokine receptor 1 (CX3CR1) and the expression of the C–C chemokine receptor type 2 (CCR2): Ly6C^highCXC3CR1⁺CCR2⁺. This subset is actively recruited to inflamed tissues and requires CCR2 for mobilization and transmigration from the bone marrow to blood and subsequently for the transmigration into these sites of inflammation.^19–22 In contrast, patrolling monocytes express Ly6C at low levels, high levels of CXC3CR1 and do not express CCR2 (Ly6C^lowCXC3CR1^brightCCR2). Their egress from bone marrow is Ccr2-independent but dependent on sphingosine-1 phosphate receptor 5 (S1pr5).²³ They have a longer half-life, crawl on the vessel luminal wall²⁴ and are recruited within the vasculature of inflamed and damaged tissues.^25,26 To date, a specific precursor for patrolling monocytes has not been identified and Ly-6C^hi monocytes are thought to give rise to Ly-6C^lo monocytes either in the blood or in the bone marrow.²⁷ C/EBPβ-dependent control of Nr4a1 expression in monocytes has been proposed as the molecular mechanism that mediates the maturation of Ly-6C^hi monocytes into Ly-6C^lo.²⁸

Human monocytes have been classified into three subtypes based on the differential expression of CD14 and CD16: classical CD14⁺⁺CD16⁻ (also referred as CD14⁺ or CD14⁺CD16⁻), intermediate CD14⁺⁺CD16⁺ (also referred as CD14⁺CD16⁺ or CD14⁺CD16^int/low) and non-classical CD14⁺CD16⁺⁺ (also referred as CD14^lowCD16⁺ or CD14^dimCD16⁺) monocytes.²⁹ The marker of human monocytes, CD14, is a glycoprotein and myelomonocytic differentiation antigen that functions as an accessory protein to toll-like receptor (TLR4).³⁰

Monocyte/macrophage lineages display a remarkable plasticity and are able to change their phenotype in response to the microenvironment, giving rise to different populations of cells with distinct functions.³¹ In damaged tissues, as in ischemic stroke, peripheral-blood monocytes could have the ability to differentiate into macrophages and further polarize into several subtypes with specific functions including the production of inflammatory molecules and phagocytic activity (Figure 1).³² To easily classify them and based on in vitro studies, two main activation states in macrophages, designated as M1 (classically activated) and M2 (alternatively activated) macrophages, have been proposed. M1 subset is mainly associated with cytotoxicity and is thought to play an important role in the killing phase of the inflammatory response, producing pro-inflammatory cytokines and ROS upon stimulation with interferon-γ (IFNγ) and lipopolysaccharide (LPS), whereas polarization of macrophages towards an M2 phenotype, induced by interleukin-4 (IL-4), IL-10 or transforming growth factor-β (TGF-β), promotes tissue repair and trophic functions.^31,33–35 Moreover, associated markers to each polarization state have been used to distinguish between these two macrophage activation states: in mice, the inducible nitric oxide synthase (iNOS) for the M1 macrophages, and the mannose receptor (CD206), arginase 1 (Arg1), chitinase-like 3 (Chil3 or Ym1) and IL-10 for the M2 ones.^36–38

In the context of cerebral ischemia, growing evidence suggests that monocytes/macrophages can contribute to both brain injury^39,40 and repair (Figure 1).^41,42 Monocytes massively infiltrate into brain infarct early after stroke.^43,44 In ischemic stroke patients, the number of peripheral monocytes is significantly increased in blood,^45–47 and a significantly positive correlation between monocyte count and NIHSS score on admission has been reported.⁴⁸ Urra et al.^45,46 also found that monocytes are major players in the prognosis and risk of infection after acute stroke. Ly6C^hi monocytes, which are the predominant CCR2-expressing monocyte cell type, requiring CCR2 for extravasation from bone marrow into blood and subsequently for transmigration into sites of inflammation,²² appear to be a prominent cell subset recruited from the circulation into the ischemic brain in mice.^49–51 As to the cytokines/chemokines involved, CCL2 (also known as monocyte chemoattractant protein 1, MCP-1) is the most potent activator of CCR2 signalling in mice, leading to monocyte transmigration after stroke. The implication of the CCL2/CCR2 axis in mediating monocyte infiltration into the inflamed tissue has also been shown in other neuroinflammatory conditions such as EAE or traumatic brain injury.^49,52,53 CCR2 knock-out mice display an increased number of monocytes in the bone marrow, a decreased number of circulating monocytes and a subsequent decrease in ischemic tissue, thus explaining that the absence of this chemokine receptor is protective against cerebral ischemia/reperfusion injury.⁵⁴ There is, however, also evidence showing that CCR2⁺ monocytes may play an important role in anti-inflammatory and recovery processes after cerebral ischemia in mice models. CCR2⁺ monocytes have been associated to the maintenance of the neurovascular unit integrity and have been implicated in mediating neuroblast migration from neurogenic regions to damaged areas of the brain after stroke.^41,55 In agreement with a pro-repairing role of CCR2⁺ monocytes after stroke, monocyte depletion during the first week after cerebral ischemia leads to impaired recovery of the sensorimotor function and drastically decreases the tissue expression of anti-inflammatory genes, including TGFβ, CD163, and Ym1.³² Also, recently, the use of CX3CR1^GFP/+CCR2^RFP/+ bone marrow chimeric mice showed that CCR2⁺Ly6C^hi monocytes are the primary monocytic cell infiltrating during the acute inflammatory response to brain ischemia. This is followed by CX3CR1⁺ cell accumulation at the border of the infarct core 14 days after MCAO. In addition, this study suggests the possibility that CCR2⁺ monocytes undergo a phenotypic transformation into CX3CR1⁺CCR2⁻ cells following infiltration to the ischemic tissue because accumulation of CX3CR1⁺Ly6C^lo monocytes was absent in the brains of CCR2-deficient mice, which exhibit deficiency in CCR2⁺Ly6C^hi recruitment, but not in NR4A1^−/− chimeric mice, which lack circulating CX3CR1⁺Ly6C^lo monocytes.⁵¹ These findings strengthen the idea of the presence of different effector functions driven by monocytes/macrophages after CNS injury that play a pleiotropic role in mediating brain injury and repair. In addition, monocyte infiltration into the ischemic tissue follows a spatiotemporal pattern whose consequences are currently not well understood.

In this regard, immunoregulatory and anti-inflammatory cytokines released after stroke, such as IL-4, IL-10 and TGF-β, could influence monocyte/macrophage activation, fate and functionality.³¹ In the context of cell activation, only a few experimental studies have evaluated the therapeutic benefits of drugs acting by increasing the M2/M1 ratio in stroke. Among these, Amantea et al.⁵⁶ have demonstrated that acute treatment with azithromycin attenuates blood–brain barrier (BBB) damage and cerebral ischemic damage in rodents subjected to MCAO, with a significant amelioration of neurological deficits up to seven days after the insult. Even more, chronic metformin treatment was reported to promote functional recovery and tissue repair via AMPK-dependent turning microglia/macrophages toward an M2 phenotype in mice after MCAO,⁵⁷ and up-regulation of M2 markers has also been shown to underlie neuroprotection by exendin-4, used in clinic against type 2 diabetes, when administrated in young healthy and in aged diabetic/obese after MCAO.⁵⁸ As it will be discussed below, the differential role of infiltrating monocytes/macrophages vs. resident microglia in these settings remains to be accurately established. Moreover, phenotypic characterization of myeloid subsets using the M1/M2 paradigm of activation could not reflect the real diversity and functionality of these cells in the context of brain inflammation as it relies on the assumption that a macrophage genetic program is recapitulated by the culture of monocyte-derived macrophages (MDMs). In this regard, identification of specific myeloid subsets with specific functions could be more useful to understand the diversity of the myeloid compartment in the context of stroke pathogenesis.

Microglia

Microglia derives from an extraembryonic erythromyeloid precursor and persist in adult mice independently of haematopoiesis.^59,60 Therefore, they are not normally replaced by bone marrow-derived cells,⁶¹ strongly suggesting that these cells have an elaborate repertoire of brain-specific functions that may not be appropriately taken over by peripheral monocytes/macrophages. Microglial cells are the first immune responders in the CNS. Upon cerebral injury microglial processes quickly and autonomously converge on the site of the damage (Figure 1).

An increasing number of studies suggest that resident microglia are functionally distinct from HSC-derived macrophages and play unique roles within the CNS.^22,62–64 Since the lack of reliable microglia-specific markers has made very difficult to discriminate between microglia and infiltrated MDMs in the inflamed brain, an essential step to allocate differential functions to these cell types requires being able to conclusively distinguish them from each other. One of the most common approaches is the observation that, in contrast to macrophages, microglia expresses low or intermediate levels of the leukocyte marker CD45. This allows the characterization of microglia by flow cytometry using the levels of expression of CD45 in CD11b⁺ cells, a myeloid marker similarly expressed in both resident and non-resident populations.^65–67 Although, by flow cytometry, MDMs can be differentiated by the expression level of CD45 and Ly6C,⁶⁸ however, these cells down-regulate the expression of Ly6C after entry into the CNS.⁵¹ Different in vivo strategies have been established to attempt this discrimination after stroke, such as adoptive transfer studies of infiltrating cells using bone marrow chimeric mice with labelled bone marrow cells (DsRed; red fluorescent reporter) replaced after irradiation, to characterize the phenotype of macrophages entering the ischemic cortex.⁶⁹ The main limitation of this technique is that it might harm the CNS by affecting the integrity of the BBB,⁷⁰ so it is important to protect the heads of recipient mice from irradiation by head shielding.⁴⁹ Complementary data on the recruitment of peripheral myeloid cells into the CNS have been obtained by parabiosis. However, the rate of chimerism in the parabiosis model is generally low compared to irradiation, which might lead to an underestimation of myeloid cell engraftment.^52,71 Also, in situ CFSE (carboxyfluorescein succinimidyl ester)-labelling of blood-derived cells has been extensively used in different models of cerebral ischemia,^43,44,62,72 but this molecule labels all proliferating blood cells and may not be ideal for purifying cells for gene expression analysis. One of the best approaches in the recent years has been the use of genetically modified mouse models such as the LysM-EGFP knock-in transgenic mouse, in which EGFP is inserted into the lysozyme M locus labelling neutrophils and hematogenous macrophages but not microglia.^73–76 This EGFP labelling helps to distinguish MDMs that have entered the damaged CNS from microglia that are LysMEGFP-negative and was confirmed using microglia-specific antibodies.⁷⁵ Zarruk et al.⁷⁷ used for the first time LysM-EGFP knock-in mice to separate MDMs from microglia by FACS and purified cell populations for expression analysis after ischemic stroke. They performed a PCR-array screen of 84 inflammatory genes revealing that pro-inflammatory chemokines and cytokines were predominantly upregulated in macrophages but down-regulated in microglia in the ischemic brain. These results show clear differences in the inflammatory expression profiles of microglia and macrophages 72 h post-ischemia which may shape repair and pro-regenerative mechanisms after stroke. A very good model to specifically label microglia is the Cx3cr1-ertCre.⁷⁸

As previously indicated for macrophages, an M1- or M2-like activation has also been suggested to occur in microglia. In vitro studies in which primary microglial cultures were exposed to LPS or IFNγ showed the induction of an M1-like phenotype with reduced phagocytic activity and expression of IL-1β, TNFα, iNOS or IL-6, while IL-4 drives microglia towards a M2-like phenotype with increased Arg1, Ym1 and resistin-like α (FIZZ1) expression.⁷⁹ Although M1/M2 activation can also take place in microglial cell cultures, it must be taken into account that, as previously indicated for monocytes, brain microglial gene expression signature could be lost in primary microglial cell cultures as well as in microglial cell lines such as BV2.⁵³ Considering this limitation, in vivo M1/M2 activation of microglia has been proposed as a potential therapeutic option in different diseases.^79–81

In stroke, modulation of the M1 and M2 phenotype in microglia/macrophages (Figure 1) has been linked to detrimental and neuroprotective actions, respectively (see, for instance, see Han et al.⁸²). Further studies on different CNS pathologies such as traumatic brain injury or spinal cord injury also indicate that microglia shift from a transient M2 phenotype to become M1-like phagocytes.^36,83 However, a major caveat of these studies relies on the characterization of the brain myeloid cells that express a limited array of M1/M2 markers that could not reflect the current activation state of the cell. In this regard, recent studies on AD using single-cell transcriptomics identified a novel microglial type associated with neurodegenerative diseases (disease-associated microglia or DAM) with a unique potential to restrict neurodegeneration⁸⁴ that indicates a high degree of specialization in response to pathogenic stimuli of this myeloid subset that falls beyond the M1/M2 dichotomy.

Neutrophils

Within the leukocyte populations, neutrophils play a key role in the innate immune response. They act as a fundamental defence in diseases associated with infections but also in sterile inflammation (as in stroke, cancer, autoimmune diseases, etc.). Their role in defence against pathogens has been extensively studied. Their ability to phagocytose and release molecules into their environment is well known.⁸⁵ In addition, in response to different stimuli, neutrophils release neutrophil extracellular traps (NETs), which are large web-like structures composed of histones, DNA, and granule proteins, such as elastase and MPO.⁸⁶ Although NETs primary function is to trap, restrain, and neutralize invading microbes,⁸⁷ their role in diseases associated with sterile inflammation is increasingly demonstrated.

The bone marrow produces 10¹⁰ neutrophils per day. There, they will mature acquiring a high content in granules equipped with various proteins involved in the modulation of the immune response.⁸⁸ Following maturation, neutrophils are released to the bloodstream where their half-life has been estimated to be 6 to 12 h, both in mice and humans.⁸⁵ After that time, they are thought to undergo spontaneous apoptosis being then eliminated in different organs through phagocytosis.⁸⁹ Besides circulating in the bloodstream, neutrophils can also be found in marginated pools in tissues such as the spleen and the lungs.⁹⁰ Importantly, neutrophil biology can be altered by different situations. For example, their life span increases when an inflammatory process occurs. This process, called priming, expands neutrophils half-life when exposed to certain cytokines.⁹¹ It has been recently demonstrated that neutrophils are able to travel back to the bloodstream after they have infiltrated into an injured tissue. This process, so-called reverse transmigration, could explain such increased life span.⁹²

In response to inflammatory stimuli, neutrophils activate and contribute to the resolution of inflammation, to inflammation-associated immunopathology or to the modulation of the adaptive immune responses. Ischemic damage leads to neuroinflammation and cell death. Necrotic cells release pro-inflammatory cytokines that will induce subsequent neutrophil infiltration to the ischemic tissue. Neutrophils are the first leukocytes to be recruited into the parenchyma,⁹³ reaching the peak of infiltration between 48 and 72 h after the insult.⁹⁴ This process is facilitated by the characteristic disruption of the BBB that takes place after stroke (Figure 2).⁹⁵ The presence of neutrophils in the ischemic tissue contributes to stroke-associated brain injury, oedema and also to BBB disruption. Many mechanisms underlie these effects, such as the synthesis/release of cytokines and chemokines and the production of ROS. In the bloodstream, neutrophils respond to cytokines such as TNFα, IL1β, IL6 and IL8. Also, they can be activated by DAMPS (damage-associated molecular patterns) like HMGB1 or HSP72 via the TLR family (Figure 2).⁹⁶ Aside from the above mentioned, other molecules can modulate neutrophil migration, such as the leukotriene B4, that is required to recruit neutrophils to the lesion site.⁹⁷

The specific role of neutrophils in brain ischemia is currently under debate (Figure 2). Classically, neutrophils have been shown to be mainly detrimental, by mechanisms that will affect outcome, severity and infarct volume. For instance, neutrophils account for the no-reflow phenomenon, increasing tissue damage.⁹⁸ Even more, they can contribute to tissue injury through the release of elastase which damages the parenchyma and the production of ROS that contribute to BBB disruption.⁹⁹ In this context, as we will discuss below, the formation and release of NETs within blood vessels may contribute to the formation of heterotypic aggregates, thus contributing to inflammation and thrombosis. However, in spite of their implication in tissue damage, there is not a clear correlation between the number of circulating neutrophils and the extent of the ischemic lesion.¹⁰⁰ In this context, neutrophils are instrumental for the resolution of inflammation and their phagocytic activity contributes to the elimination of the necrotic tissue. In addition, other factors, such as the existence of neutrophil subsets with different roles in stroke pathogenesis, may account for possible beneficial actions of these cells. In this manner, the view of neutrophils as a homogeneous population is changing and nowadays it is believed that there are neutrophil subpopulations that exhibit different characteristics with anti-inflammatory, angiogenic or pro-resolutive properties. One of the first studies to describe the heterogeneity of neutrophil populations was published in the context of cancer and showed the existence of tumour-associated neutrophils (TANs), a subset of neutrophils that was named, by analogy to the macrophages M1/M2 paradigm, as N2 neutrophils or pro-tumorigenic.¹⁰¹ On the other side of this dichotomy, these authors found a population of neutrophils within the tumour that exhibited a pro-inflammatory profile and that was named as N1. The shift towards one or the other phenotype was determined by the environment. For example, the presence of IL-10, TGFβ, IL-13 and IL-4 would induce N2 polarization, whereas the presence of IFNβ, IFNγ and IL-12 would favour N1 polarization.¹⁰² A similar heterogeneity in the neutrophil compartment has been described by our group in the setting of stroke (Figure 2). Immunofluorescence characterization of the expression of prototypical M2 markers in ischemic tissue revealed that neutrophils located in the lesion differentially expressed some of these markers. Moreover, this phenotypic heterogeneity was modulated by PPARγ activation with the agonist rosiglitazone, that skewed neutrophils towards an M2-like or N2 phenotype which was associated with neuroprotection and resolution of inflammation after experimental stroke induced by pMCAO.¹⁰³ Interestingly, this neutrophil subset was more efficiently cleared by microglial phagocytosis than the other subset. Through this mechanism, debris was promptly removed from the inflamed tissue by phagocytosis, contributing to the restoration of tissue homeostasis and improving the final outcome. In addition, one of the most accepted views proposes that there are different populations of neutrophils depending on their age: fresh neutrophils, recently released from the bone marrow, display a set of surface markers different to those present in aged neutrophils, close to be cleared away from the bloodstream.^104,105 It has also been reported that neutrophil pro-inflammatory activity correlates positively with their ageing, while in circulation, a process driven by the microbiota via TLRs and MyD88-mediated signalling pathways.¹⁰⁶ Consistently, our group has recently observed that a member of the TLR family, TLR4, one of the main actors for the initiation of inflammation in acute stroke,¹⁰⁷ also plays a major role in the modulation of the neutrophil phenotype (García-Culebras et al., unpublished).

Platelets

Platelets, or thrombocytes, are small non-nucleated cell fragments derived from a myeloid progenitor that circulate in the bloodstream. They are well-known for their role in thrombosis and haemostasis. Notably, an increasing number of studies indicate that platelets also play a critical part in inflammation (Figure 3).^108,109

Under physiological conditions, platelets circulate in a quiescent state; however, when they become activated, platelets are able to express and release different inflammatory mediators, such as cytokines, chemokines and surface molecules^110–113 to recruit leukocytes to the site of inflammation or injury (Figure 3). Many of these molecules are stored in platelet granules, of which three different types, dense-granules, α-granules and lysosomes, have been described, each of which is rich in certain chemicals that have an important role in platelet function.

Released from dense granules, ADP and ATP play a key role in inflammation and ischemia-reperfusion injury during platelet activation;¹¹⁴ serotonin has been implicated in neutrophil rolling and adhesion to inflamed endothelium.¹¹⁵ Moreover, inorganic polyphosphates (PolyP), also released upon platelet activation, have been suggested to cause neutrophil accumulation and increase vascular permeability,^116,117 although their role has recently been questioned.¹¹⁸ The regulation of neuroinflammation by modulating the expression of platelet adhesion receptors interacting with leukocytes or by releasing cytokines that affect leukocyte function is mediated by proteins stored in α-granules.^109,119,120 Platelet factor 4 (PF4), the most abundant protein secreted from α-granules, acts as a chemoattractant for monocytes and neutrophils.¹²¹ PF4 also promotes neutrophil granule release and adhesion to endothelial cells, mediated by L-selectin and leukocyte function antigen 1 (LFA-1).¹²² PF4 induces cytokine release from monocytes including CXCL8, CXCL3, IL-1α, IL-1β, IL-6, IL-19, TNFα, CCL2, CCL3 and CCL22.¹²³ The chemokine RANTES (regulated on activation normal T cell expressed and secreted) is released either directly or in microparticles which can be immobilised on activated endothelium and promote monocyte recruitment by P-selectin.^124,125 T cells can also induce platelet RANTES release promoting T cell recruitment to the endothelium.¹²⁶ Among other platelet-derived chemokines, macrophage inflammatory protein- (MIP-) 1α is a chemoattractant for monocytes, macrophages, T-cells and neutrophils, and is involved in transendothelial migration at sites of inflammation.¹²⁷ When platelets become activated, they also release IL-1 which has a major role in vascular inflammation.¹²⁸ IL-1 is known to promote neutrophil adhesion to endothelial cells and mediate vascular NO production.^129,130 Platelet-secreted IL-1α causes endothelial activation which leads to the expression of ICAM-1 and VCAM-1 adhesion molecules on endothelial cells, CXCL1 release, and neutrophil transendothelial migration.¹³¹ Another constituent of platelet α-granules is P-selectin,¹³² an important adhesion molecule which, in response to activating signals, is translocated to the surface of platelets and binds to P-selectin glycoprotein ligand-1 (PSGL-1) on immune cells.¹³³ In vitro studies have suggested that leukocytes can roll and adhere to immobilized platelets adherent in the vessel wall causing a pro-inflammatory state.¹³⁴ This result was corroborated in the cerebral ischemia setting by an in vivo study revealing that platelets modulate leukocyte recruitment via P-selectin in a mouse tMCAO model (Figure 3).¹³⁵ In addition, our group has described in a mouse pMCAO model that, at early stages of inflammation, neutrophils recruited to the injured vessel use their PSGL-1 domain to scan for the presence of activated platelets, as a primary mechanism for the initiation of the inflammation process.¹³⁶

Specifically, platelet–neutrophil crosstalk leading to the formation of NETS is being increasingly recognised as a driver of inflammation and thrombosis. In this context, cell activation appears to be bidirectional.¹³⁷ Activated platelets can stimulate neutrophils to release NETs,^86,138 for instance, through P-selectin and PSGL-1 binding.¹³⁹ In addition, neutrophils-derived NETs can activate platelets, a process in which TLR-dependent mechanisms may be involved (Figure 3).^140,141 NET formation, by leading to the formation of heterotypic aggregates within blood vessels, is likely to have a large impact on the outcome of inflammatory processes. Specifically, signs of NET formation have been described in perivascular spaces, in the brain parenchyma nearby blood vessels, and in the lumen of capillaries in the ischemic brain in the tMCAO model.¹⁴² Importantly, the administration of DNase I, which degrades NETs, has been shown to have a protective in vivo effect in murine models after ischemic stroke.¹⁴³ To date, NETs have been detected in venous and arterial thrombosis in patients.^140,144 Recent studies showed that thrombus NETs content is associated with poor outcome in cerebral ischemia and may be responsible for reperfusion resistance, including mechanical or pharmacological approaches with intravenous t-PA.^145,146 Even more, Vallés et al.¹⁴⁷ not only found that NETs were significantly elevated in the plasma of acute ischemic stroke patients when compared to healthy subjects, but also that NETs levels were increased in patients who were over 65 years of age or with a history of atrial fibrillation (AF), cardioembolic stroke, high glucose levels, and severe stroke scores at admission and discharge. However, data are still scarce and further studies are required to establish their role in stroke patients.

Figure 1.

Circulating and infiltrated monocytes and resident microglia participate actively in an immune-inflammatory scenario after stroke. In this environment, these cells are able to respond to different signals, modulate their response and change their phenotype (M1/M2 polarization). Different mechanisms could be proposed as possible targets for modulating the neuroinflammation process.

Modulation of neutrophil function as a novel therapeutic target in neuroinflammation

All the aforementioned data evidence the high degree of plasticity of the myeloid system. Monocytes, neutrophils and microglia have been described to play different functions and to be composed by heterogeneous cell populations with specialized functions that could be exploited to investigate novel therapeutic targets for the treatment of brain damage associated to neuroinflammation after stroke. The importance of monocytes/macrophages and microglial cells in this context has been thoroughly reviewed.¹⁴⁸ Importantly, growing evidence supports the therapeutic interest of neutrophils and their interaction with platelets.

The inhibition of neutrophil recruitment to the ischemic tissue is a strategy that could be theoretically approached by targeting the signalling pathways involved (Figure 2). In this context, combined pharmacological inhibition of CXCR1 and CXCR2 reduced ischemic brain injury and improved outcome in a rat stroke model,¹⁴⁹ although this improvement did not occur when only CXCR2 was blocked.¹⁵⁰ CCR2 loss of function using CCR2^−/− mice reduced the infarct volume and neutrophil infiltration but this target is not neutrophil-specific as it also acts on monocyte recruitment to the ischemic tissue.⁵⁴ A promising target for the early phases of acute stroke at the level of neutrophil recruitment to the ischemic tissue is the inhibition of the P-selectin-PSGL-1 interaction that leads to platelet–neutrophil adhesion, a process that is neuroprotective in experimental models of stroke.¹³⁶

Figure 2.

Neutrophils, under inflammatory conditions, activate and contribute to the inflammatory process and its resolution. They are able to skew to different phenotypes (including N1/N2 polarization), produce and release different cytokines, form platelets–neutrophil complexes, adhere to the endothelium and infiltrate into damaged tissues. All these steps are potential targets to modulate neuroinflammation.

A related potential approach is to impede neutrophil infiltration (Figure 2). This process is mediated by integrins and selectins. The blockade of ICAM-1 showed some promising results in animal models but failed to be effective in patients.^151,152 The effect of blocking LFA1 (CD11a/CD18) and Mac1(CD11b/CD18), which mediate neutrophil adhesion through ICAM1 and ICAM2 in endothelial cells, has also been explored.^153–155 Again, the results have been different depending on the timing and the model used. Inhibiting LFA1 and Mac1 have been tried out in patients with no success.^156,157 It should be noted that the infiltration of neutrophils into the ischemic tissue is considered controversial. Some authors even claim that neutrophils do not infiltrate into the parenchyma but remain in the perivascular spaces,¹⁵⁸ an effect that could depend on the ischemia model used, transient or permanent occlusion, as the presence of neutrophils within the brain parenchyma has also been shown.¹⁰³ A crucial issue that needs to be emphasised is the relevance of reperfusion for post-stroke inflammatory response. An interesting possibility is that neutrophils have different fates and/or roles depending on their final location, either within the vasculature or into the parenchyma of the ischemic tissue. In relation with the intravascular location, an additional aspect to be considered is the interaction of neutrophils with platelets and the subsequent release of NETs which may lead to vascular “thromboinflammatory” injury.¹⁵⁹ The understanding of these processes may provide new opportunities for the development of novel therapeutic strategies in ischemic stroke that remain to be studied.

Neutrophil-mediated detrimental effects are also possible targets (Figure 2). Neutrophils contribute to the disruption of the BBB through the release of proteases (such as MMP-9 and elastase) and ROS. MMP-9 has been correlated with BBB disruption and haemorrhagic transformation both in animal models and patients,¹⁶⁰ and elastase promotes the degradation of the basal lamina and the extracellular matrix.⁹⁹ Pharmacological and genetic approaches to block these molecules have showed promising results in animal models.^161,162 However, this potential therapy remains to be proved beneficial in patients, especially considering the potential reparative actions of MMP-9, also known to promote angiogenesis/neurogenesis in the chronic phase of stroke (see, for instance, Lee et al.,¹⁶³ Barkho et al.¹⁶⁴ and Hao et al.¹⁶⁵).

Figure 3.

Platelets switch between a quiescent state to an activated one under inflammatory conditions and release different inflammatory mediators from their storage compartments into circulation. They are capable of interacting with neutrophils through P-selectin. This neutrophil–platelet interaction is bidirectional. Activated platelets can induce NETs formation and, also, NET components can activate platelets. Theoretically, these steps could be manipulated in order to modulate the neuroinflammation process.

Finally, the modulation of neutrophil phenotype towards phenotypes with pro-resolving properties in stroke is an interesting novel therapeutic possibility (Figure 2), aiming to specific targets such as, for instance, PPARγ and TLR receptors.^103,106

In summary, current knowledge underlines the importance of the identification of the myeloid cell subsets directly associated to neuroprotection after stroke. In addition, it is also essential to characterize specific states of activation in myeloid cells associated to brain ischemia and to explore the signalling pathways by which these states determine stroke progression and outcome, as well as the mechanisms and consequences of platelet–leukocyte interactions. The comprehension of these processes may pave the way to novel therapeutic avenues to stop the cytotoxic phase of the inflammatory response and to promote neuroprotection and tissue repair after ischemic stroke. Furthermore, a better characterization of the myeloid cell subsets that orchestrate the response to brain ischemia and their dynamics may help us to design specific treatments within specific therapeutic windows with the aim to increase the benefits of the modulation of cell–cell interactions in the immune response after stroke.

Footnotes

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from Spanish Ministry of Economy and Competitiveness SAF2015-68632-R (MAM) and SAF2016-81716-REDC (MAM), from Instituto de Salud Carlos III and cofinanced by Fondo Europeo de Desarrollo Regional (FEDER) «Una manera de hacer Europa» PI17/01601 (IL) and RD16/0019/0009 (IL), and from Regional Madrid Government B2017/BMD-3688 (IL).

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Chamorro

Meisel

Planas

et al.

The immunology of acute stroke. Nat Rev Neurol 2012; 8: 401–410.

Iadecola

Anrather

. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 796–808.

Kamel

Iadecola

. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 2012; 69: 576–581.

Amantea

Tassorelli

Petrelli

et al.

Understanding the multifaceted role of inflammatory mediators in ischemic stroke. Curr Med Chem 2014; 21: 2098–2117.

. A new penumbra: transitioning from injury into repair after stroke. Nat Med 2008; 14: 497–500.

Moskowitz

Iadecola

. The science of stroke: mechanisms in search of treatments. Neuron 2010; 67: 181–198.

Mantovani

Biswas

Galdiero

et al.

Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229: 176–185.

Jaillon

Peri

Delneste

et al.

The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204: 793–804.

Amantea

Micieli

Tassorelli

et al.

Rational modulation of the innate immune system for neuroprotection in ischemic stroke. Front Neurosci 2015; 9: 147.

10.

Jaillon

Galdiero

Del Prete

et al.

Neutrophils in innate and adaptive immunity. Semin Immunopathol 2013; 35: 377–394.

11.

Gomez-Moreno

Adrover

Hidalgo

. Neutrophils as effectors of vascular inflammation. Eur J Clin Invest. Epub ahead of print 12 April 2018. DOI: 10.1111/eci.12940.

12.

Auffray

Sieweke

Geissmann

. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669–692.

13.

Ginhoux

Jung

. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol 2014; 14: 392–404.

14.

Saha

Geissmann

. Toward a functional characterization of blood monocytes. Immunol Cell Biol 2011; 89: 2–4.

15.

Nahrendorf

Swirski

Aikawa

et al.

The healing myocardium sequentially mobilizes two monocyte sub sets with divergent and complementary functions. J Exp Med 2007; 204: 3037–3047.

16.

Bain

Bravo-Blas

Scott

et al.

Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol 2014; 15: 929–937.

17.

Hoeffel

Wang

Greter

et al.

Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J Exp Med 2012; 209: 1167–1181.

18.

Serbina

Jia

Hohl

et al.

Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008; 26: 421–452.

19.

Boring

Gosling

Chensue

et al.

Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100: 2552–2561.

20.

Kuziel

Morgan

Dawson

et al.

Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A 1997; 94: 12053–12058.

21.

Rutledge

et al.

Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998; 187: 601–608.

22.

Chu

Arumugam

Gelderblom

et al.

Role of CCR2 in inflammatory conditions of the central nervous system. J Cereb Blood Flow Metab 2014; 34: 1425–1429.

23.

Debien

Mayol

Biajoux

et al.

S1PR5 is pivotal for the homeostasis of patrolling monocytes. Eur J Immunol 2013; 43: 1667–1675.

24.

Geissmann

Jung

Littman

. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71–82.

25.

Auffray

Fogg

Garfa

et al.

Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666–670.

26.

Carlin

Stamatiades

Auffray

et al.

Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 2013; 153: 362–375.

27.

Yona

Kim

Wolf

et al.

Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013; 38: 79–91.

28.

Mildner

Schönheit

Giladi

et al.

Genomic characterization of murine monocytes reveals C/EBPβ transcription factor dependence of Ly6C. Immunity 2017; 46: 849–862.e847.

29.

Ziegler-Heitbrock

Ancuta

Crowe

et al.

Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74–80.

30.

Wacleche

Tremblay

Routy

et al.

The biology of monocytes and dendritic cells: contribution to HIV pathogenesis. Viruses 2018. 10: pii: E65. DOI: 10.3390/v10020065.

31.

Gordon

Martinez

. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593–604.

32.

Wattananit

Tornero

Graubardt

et al.

Monocyte-derived macrophages contribute to spontaneous long-term functional recovery after stroke in mice. J Neurosci 2016; 36: 4182–4195.

33.

Hao

Fan

et al.

Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012: 948098.

34.

Benakis

Garcia-Bonilla

Iadecola

et al.

The role of microglia and myeloid immune cells in acute cerebral ischemia. Front Cell Neurosci 2014; 8: 461.

35.

Mantovani

Sica

Sozzani

et al.

The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677–686.

36.

Guo

et al.

Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 2012; 43: 3063–3070.

37.

Liu

et al.

Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One 2013; 8: e54841.

38.

Murray

Allen

Biswas

et al.

Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14–20.

39.

Tang

Gan

Liu

et al.

CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J Neuroinflammation 2014; 11: 26.

40.

Bao

Kim

Bhosle

et al.

A role for spleen monocytes in post-ischemic brain inflammation and injury. J Neuroinflammation 2010; 7: 92.

41.

Gliem

Mausberg

Lee

et al.

Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol 2012; 71: 743–752.

42.

Gliem

Krammes

Liaw

et al.

Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia 2015; 63: 2198–2207.

43.

Denes

Vidyasagar

Feng

et al.

Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab 2007; 27: 1941–1953.

44.

Schilling

Besselmann

Muller

et al.

Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2005; 196: 290–297.

45.

Urra

Villamor

Amaro

et al.

Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 2009; 29: 994–1002.

46.

Urra

Cervera

Obach

et al.

Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke 2009; 40: 1262–1268.

47.

Pusch

Debrabant

Molnar

et al.

Early dynamics of P-selectin and interleukin 6 predicts outcomes in ischemic stroke. J Stroke Cerebrovasc Dis 2015; 24: 1938–1947.

48.

Kaito

Araya

Gondo

et al.

Relevance of distinct monocyte subsets to clinical course of ischemic stroke patients. PLoS One 2013; 8: e69409.

49.

Mildner

Schmidt

Nitsche

et al.

Microglia in the adult brain arise from Ly-6ChiCCR2 + monocytes only under defined host conditions. Nat Neurosci 2007; 10: 1544–1553.

50.

Chu

Broughton

Kim

et al.

Evidence that Ly6C(hi) monocytes are protective in acute ischemic stroke by promoting M2 macrophage polarization. Stroke 2015; 46: 1929–1937.

51.

Garcia-Bonilla

Faraco

Moore

et al.

Spatio-temporal profile, phenotypic diversity, and fate of recruited monocytes into the post-ischemic brain. J Neuroinflammation 2016; 13: 285.

52.

Ajami

Bennett

Krieger

et al.

Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011; 14: 1142–1149.

53.

Butovsky

Jedrychowski

Moore

et al.

Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci 2014; 17: 131–143.

54.

Dimitrijevic

Stamatovic

Keep

et al.

Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 2007; 38: 1345–1353.

55.

Yan

Sailor

Lang

et al.

Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab 2007; 27: 1213–1224.

56.

Amantea

Certo

Petrelli

et al.

Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype. Exp Neurol 2016; 275(Pt 1): 116–125.

57.

Jin

Cheng

Liu

et al.

Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun 2014; 40: 131–142.

58.

Darsalia

Hua

Larsson

et al.

Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One 2014; 9: e103114.

59.

Kierdorf

Katzmarski

Haas

et al.

Bone marrow cell recruitment to the brain in the absence of irradiation or parabiosis bias. PLoS One 2013; 8: e58544.

60.

Schulz

Gomez Perdiguero

Chorro

et al.

A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336: 86–90.

61.

Kierdorf

Erny

Goldmann

et al.

Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 2013; 16: 273–280.

62.

Denes

McColl

Leow-Dyke

et al.

Experimental stroke-induced changes in the bone marrow reveal complex regulation of leukocyte responses. J Cereb Blood Flow Metab 2011; 31: 1036–1050.

63.

Girard

Brough

Lopez-Castejon

et al.

Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia 2013; 61: 813–824.

64.

Moraga

Pradillo

Garcia-Culebras

et al.

Aging increases microglial proliferation, delays cell migration, and decreases cortical neurogenesis after focal cerebral ischemia. J Neuroinflammation 2015; 12: 87.

65.

Campanella

Sciorati

Tarozzo

et al.

Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 2002; 33: 586–592.

66.

Denker

Dingman

et al.

Macrophages are comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke. J Neurochem 2007; 100: 893–904.

67.

Ballesteros

Cuartero

Pradillo

et al.

Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways. J Leukoc Biol 2014; 95: 587–598.

68.

Ritzel

Patel

Grenier

et al.

Functional differences between microglia and monocytes after ischemic stroke. J Neuroinflammation 2015; 12: 106.

69.

Miro-Mur

Urra

Gallizioli

et al.

Antigen presentation after stroke. Neurotherapeutics 2016; 13: 719–728.

70.

Yuan

Gaber

McColgan

et al.

Radiation-induced permeability and leukocyte adhesion in the rat blood-brain barrier: modulation with anti-ICAM-1 antibodies. Brain Res 2003; 969: 59–69.

71.

Ajami

Bennett

Krieger

et al.

Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007; 10: 1538–1543.

72.

Kokovay

Cunningham

. Angiogenic recruitment of pericytes from bone marrow after stroke. J Cereb Blood Flow Metab 2006; 26: 545–555.

73.

Faust

Varas

Kelly

et al.

Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 2000; 96: 719–726.

74.

Greenhalgh

David

. Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J Neurosci 2014; 34: 6316–6322.

75.

Greenhalgh

Passos Dos Santos

Zarruk

et al.

Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease. Brain Behav Immun 2016; 56: 61–67.

76.

Mawhinney

Thawer

et al.

Differential detection and distribution of microglial and hematogenous macrophage populations in the injured spinal cord of lys-EGFP-ki transgenic mice. J Neuropathol Exp Neurol 2012; 71: 180–197.

77.

Zarruk

Greenhalgh

David

. Microglia and macrophages differ in their inflammatory profile after permanent brain ischemia. Exp Neurol 2018; 301: 120–132.

78.

Goldmann

Wieghofer

Muller

et al.

A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 2013; 16: 1618–1626.

79.

Michelucci

Heurtaux

Grandbarbe

et al.

Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol 2009; 210: 3–12.

80.

Cherry

Olschowka

O'Banion

. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014; 11: 98.

81.

David

Kroner

. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 2011; 12: 388–399.

82.

Han

Cai

Mao

et al.

Rosiglitazone promotes white matter integrity and long-term functional recovery after focal cerebral ischemia. Stroke 2015; 46: 2628–2636.

83.

Shechter

London

Varol

et al.

Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009; 6: e1000113.

84.

Keren-Shaul

Spinrad

Weiner

et al.

A unique microglia type associated with restricting development of Alzheimer's disease. Cell 2017; 169: 1276–1290.e1217.

85.

Kolaczkowska

Kubes

. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13: 159–175.

86.

Metzler

Goosmann

Lubojemska

et al.

A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. Cell Rep 2014; 8: 883–896.

87.

Brinkmann

Reichard

Goosmann

et al.

Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532–1535.

88.

Borregaard

. Neutrophils, from marrow to microbes. Immunity 2010; 33: 657–670.

89.

Hong

Kidani

A-Gonzalez

et al.

Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J Clin Invest 2012; 122: 337–347.

90.

Summers

Rankin

Condliffe

et al.

Neutrophil kinetics in health and disease. Trends Immunol 2010; 31: 318–324.

91.

Colotta

Polentarutti

et al.

Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992; 80: 2012–2020.

92.

Mathias

Perrin

Liu

et al.

Resolution of inflammation by retrograde chemotaxis of neutrophils in transgenic zebrafish. J Leukoc Biol 2006; 80: 1281–1288.

93.

Kim

Park

Chang

et al.

Inflammation after ischemic stroke: the role of leukocytes and glial cells. Exp Neurobiol 2016; 25: 241–251.

94.

Jickling

Liu

Ander

et al.

Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab 2015; 35: 888–901.

95.

Yang

Rosenberg

. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42: 3323–3328.

96.

Prince

Whyte

Sabroe

et al.

The role of TLRs in neutrophil activation. Curr Opin Pharmacol 2011; 11: 397–403.

97.

Lämmermann

Afonso

Angermann

et al.

Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 2013; 498: 371–375.

98.

Ames

Wright

Kowada

et al.

Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol 1968; 52: 437–453.

99.

Ikegame

Yamashita

Hayashi

et al.

Neutrophil elastase inhibitor prevents ischemic brain damage via reduction of vasogenic edema. Hypertens Res 2010; 33: 703–707.

100.

Strecker

Sevimli

Schilling

et al.

Effects of G-CSF treatment on neutrophil mobilization and neurological outcome after transient focal ischemia. Exp Neurol 2010; 222: 108–113.

101.

Fridlender

Sun

Kim

et al.

Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009; 16: 183–194.

102.

Sionov

Fridlender

Granot

. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron 2015; 8: 125–158.

103.

Cuartero

Ballesteros

Moraga

et al.

N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARγ agonist rosiglitazone. Stroke 2013; 44: 3498–3508.

104.

Adrover

Nicolás-Ávila

Hidalgo

. Aging: a temporal dimension for neutrophils. Trends Immunol 2016; 37: 334–345.

105.

Casanova-Acebes

Pitaval

Weiss

et al.

Rhythmic modulation of the hematopoietic niche through neutrophil clearance. Cell 2013; 153: 1025–1035.

106.

Zhang

Chen

Manwani

et al.

Neutrophil ageing is regulated by the microbiome. Nature 2015; 525: 528–532.

107.

Caso

Pradillo

Hurtado

et al.

Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007; 115: 1599–1608.

108.

Ghoshal

Bhattacharyya

. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J 2014; 2014: 781857.

109.

Thomas

Storey

. The role of platelets in inflammation. Thromb Haemost 2015; 114: 449–458.

110.

Shi

Morrell

. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res 2011; 127: 387–390.

111.

Boehlen

Clemetson

. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice?. Transfus Med 2001; 11: 403–417.

112.

Smyth

McEver

Weyrich

et al.

Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7: 1759–1766.

113.

Golebiewska

Poole

. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev 2015; 29: 153–162.

114.

Eltzschig

Sitkovsky

Robson

. Purinergic signaling during inflammation. N Engl J Med 2013; 368: 1260.

115.

Duerschmied

Suidan

Demers

et al.

Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121: 1008–1015.

116.

Müller

Mutch

Schenk

et al.

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143–1156.

117.

Morrissey

Choi

Smith

. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972–5979.

118.

Faxälv

Boknäs

Ström

et al.

Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII. Blood 2013; 122: 3818–3824.

119.

Herter

Rossaint

Zarbock

. Platelets in inflammation and immunity. J Thromb Haemost 2014; 12: 1764–1775.

120.

Jenne

Urrutia

Kubes

. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 2013; 35: 254–261.

121.

Deuel

Senior

Chang

et al.

Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A 1981; 78: 4584–4587.

122.

Weber

Springer

. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085–2093.

123.

Kasper

Brandt

Brandau

et al.

Platelet factor 4 (CXC chemokine ligand 4) differentially regulates respiratory burst, survival, and cytokine expression of human monocytes by using distinct signaling pathways. J Immunol 2007; 179: 2584–2591.

124.

Schober

Manka

von Hundelshausen

et al.

Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523–1529.

125.

von Hundelshausen

Koenen

Sack

et al.

Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924–930.

126.

Danese

de la Motte

Reyes

et al.

Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004; 172: 2011–2015.

127.

Lentzsch

Gries

Janz

et al.

Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101: 3568–3573.

128.

Loppnow

Libby

. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990; 85: 731–738.

129.

Bevilacqua

Pober

Wheeler

et al.

Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985; 76: 2003–2011.

130.

Ignarro

Buga

Wei

et al.

Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 2001; 98: 4202–4208.

131.

Thornton

McColl

Greenhalgh

et al.

Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115: 3632–3639.

132.

Romo

Dong

Schade

et al.

The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190: 803–814.

133.

Frenette

Denis

Weiss

et al.

P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413–1422.

134.

Hammer

Apte

. Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. Biophys J 1992; 63: 35–57.

135.

Ishikawa

Cooper

Arumugam

et al.

Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J Cereb Blood Flow Metab 2004; 24: 907–915. DOI: 10.1097/01.WCB.0000132690.96836.7F.

136.

Sreeramkumar

Adrover

Ballesteros

et al.

Neutrophils scan for activated platelets to initiate inflammation. Science 2014; 346: 1234–1238.

137.

Ghasemzadeh

Hosseini

. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state. Thromb Res 2013; 131: 191–197.

138.

Massberg

Grahl

von Bruehl

et al.

Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887–896.

139.

Etulain

Martinod

Wong

et al.

P-selectin promotes neutrophil extracellular trap formation in mice. Blood 2015; 126: 242–246.

140.

Fuchs

Brill

Duerschmied

et al.

Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107: 15880–15885.

141.

Semeraro

Ammollo

Morrissey

et al.

Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118: 1952–1961.

142.

Perez-de-Puig

Miró-Mur

Ferrer-Ferrer

et al.

Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol 2015; 129: 239–257.

143.

De Meyer

Suidan

Fuchs

et al.

Extracellular chromatin is an important mediator of ischemic stroke in mice. Arterioscler Thromb Vasc Biol 2012; 32: 1884–1891.

144.

Mangold

Alias

Scherz

et al.

Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ Res 2015; 116: 1182–1192.

145.

Laridan

Denorme

Desender

et al.

Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 2017; 82: 223–232.

146.

Ducroux

Di Meglio

Loyau

et al.

Thrombus neutrophil extracellular traps content impair tPA-induced thrombolysis in acute ischemic stroke. Stroke 2018; 49: 754–757.

147.

Vallés

Lago

Santos

et al.

Neutrophil extracellular traps are increased in patients with acute ischemic stroke: prognostic significance. Thromb Haemost 2017; 117: 1919–1929.

148.

Kanazawa

Ninomiya

Hatakeyama

et al.

Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke. Int J Mol Sci 2017. 18: pii: E2135. DOI: 10.3390/ijms18102135.

149.

Villa

Triulzi

Cavalieri

et al.

The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med 2007; 13: 125–133.

150.

Brait

Rivera

Broughton

et al.

Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome. Brain Res 2011; 1372: 169–179.

151.

Zhang

Chopp

Jiang

et al.

Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995; 26: 1438–1442, discussion 1443.

152.

Investigators EAST. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001; 57: 1428–1434.

153.

Arumugam

Salter

Chidlow

et al.

Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol 2004; 287: H2555–2560.

154.

Soriano

Coxon

Wang

et al.

Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 1999; 30: 134–139.

155.

Zhang

et al.

Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003; 34: 1790–1795.

156.

Becker

. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and enlimomab (R6.5) in acute stroke. Curr Med Res Opin 2002; 18(Suppl 2): s18–s22.

157.

Krams

Lees

Hacke

et al.

Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–2548.

158.

Enzmann

Mysiorek

Gorina

et al.

The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury. Acta Neuropathol 2013; 125: 395–412.

159.

De Meyer

Denorme

Langhauser

et al.

Thromboinflammation in stroke brain damage. Stroke 2016; 47: 1165–1172.

160.

Castellanos

Sobrino

Millán

et al.

Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007; 38: 1855–1859.

161.

Gidday

Gasche

Copin

et al.

Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289: H558–568.

162.

Stowe

Adair-Kirk

Gonzales

et al.

Neutrophil elastase and neurovascular injury following focal stroke and reperfusion. Neurobiol Dis 2009; 35: 82–90.

163.

Lee

Kim

Rogowska

et al.

Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 2006; 26: 3491–3495.

164.

Barkho

Munoz

et al.

Endogenous matrix metalloproteinase (MMP)-3 and MMP-9 promote the differentiation and migration of adult neural progenitor cells in response to chemokines. Stem Cells 2008; 26: 3139–3149.

165.

Hao

Palmer

et al.

Bone marrow-derived cells contribute to vascular endothelial growth factor-induced angiogenesis in the adult mouse brain by supplying matrix metalloproteinase-9. Stroke 2011; 42: 453–458.

Myeloid cells as therapeutic targets in neuroinflammation after stroke: Specific roles of neutrophils and neutrophil–platelet interactions

Abstract

Keywords

Introduction

Monocytes/macrophages

Microglia

Neutrophils

Platelets

Modulation of neutrophil function as a novel therapeutic target in neuroinflammation

Footnotes

Funding

Declaration of conflicting interests

References